Cat.#: ASSD-221
Description | Antifade Fluorescence Mounting Medium with DAPI (hardset) from Ace Therapeutics is used to prevent the photobleaching of fluorescent proteins and dyes during fluorescent imaging. This product contains DAPI which is a blue fluorescent DNA stain used to label cell nuclei. |
Size | 10 mL |
Applications | Cellular imaging, IHC(IF), ICC |
Mounting | Aqueous (hardset) - cures in approximately 1 hour at RT |
Antifade | Yes |
Counterstain | DAPI |
Refractive index | ≈1.45 (initial) which then increases to ≈1.518 once cured |
Emission color | Blue |
Excitation | 350 nm |
Emission | 470 nm |
Closest laser lines | 405 nm |
Cell permeable | Yes |
Storage | +4°C or -20°C long-term. |
Shipping | Shipped at 4°C |
Important | If the mounting medium solidifies prematurely during operation, simply heat the bottle to approximately 60°C and the mounting medium will reliquefy. We strongly recommend storing this product in a storage buffer containing 0.05% sodium azide and away from light. |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-147 | Rhodamine phalloidin-TRITC (AC147) | 300 tests, 100μg | inquiry |
ASSD-218 | 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) | 25 mg | inquiry |
ASSD-135 | JC-1 (AC135) | 5 mg | inquiry |
ASSD-176 | Rhodamine B isothiocyanate (AC176) | 100 mg, 500 mg | inquiry |
ASSD-191 | Fluorescein 6-Isothiocyanate, Isomer 2, 95% (AC191) | 100 mg | inquiry |
ASSD-214 | 8-Aminopyrene-1,3,6-trisulfonic acid trisodium salt (AC214) | 10 mg | inquiry |
ASSD-223 | Antifade Fluorescence Mounting Medium (aqueous) (AC223) | 10 mL | inquiry |
ASSD-185 | Cyanine 3 Maleimide, Potassium Salt (AC185) | 500 μg | inquiry |
ASSD-114 | Acridine Orange hydrochloride (AC114) | 50 mg | inquiry |
ASSD-122 | Fluorescent β2 antagonist [(±)-propranolol] (AC122) | 500 μg | inquiry |
We are committed to accelerating progress in stroke research and drug development.